tert-butoxy-N-[2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxoethyl]formamide | 337530-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butoxy-N-[2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxoethyl]formamide
• 英文别名: tert-butyl N-[2-[4-(4-chlorophenyl)piperazin-1-yl]-2-oxoethyl]carbamate
• CAS: 337530-22-0
• 化学式: C₁₇H₂₄ClN₃O₃
• 分子量: 353.849
• InChiKey: OVDAWKPZVPDYAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butoxy-N-[2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxoethyl]formamide 在 盐酸 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 1.5h， 生成 2-amino-1-(4-(4-chlorophenyl)piperazin-1-yl)ethanone hydrochloride
  参考文献：
  名称：

  Substituted dipeptides having nos inhibiting activity

  摘要：

  本发明涉及一种由公式（I）表示的化合物，其中结构变量R1-R6在此定义。

  公开号：

  US06825200B1
• 作为产物：
  描述：

  BOC-甘氨酸 、 1-(4-chlorophenyl)piperazine dihydrochloride 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 20.0h， 生成 tert-butoxy-N-[2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxoethyl]formamide
  参考文献：
  名称：

  Substituted dipeptides having nos inhibiting activity

  摘要：

  本发明涉及一种由公式（I）表示的化合物，其中结构变量R1-R6在此定义。

  公开号：

  US06825200B1

文献信息

• SUBSTITUTED DIPEPTIDES HAVING NOS INHIBITING ACTIVITY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1226159A1

  公开（公告）日：2002-07-31
• US6825200B1
  申请人：——

  公开号：US6825200B1

  公开（公告）日：2004-11-30
• [EN] SUBSTITUTED DIPEPTIDES HAVING NOS INHIBITING ACTIVITY<br/>[FR] DIPEPTIDES SUBSTITUES A ACTIVITE INHIBITRICE DES NOS
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001032690A1

  公开（公告）日：2001-05-10

  The present invention relates to a compound of the formula (I) wherein R1 is benzofuranyl substituted by halogen, or styryl substituted by halogen, R2 is phenyl, pyridyl, thienyl or thiazolyl, each of which is optionally substituted by one or more substituents, or lower alkyl optionally substituted by one or more halogen atoms, R3 is hydrogen or lower alkoxy, R?4 and R5¿ are the same or different and each is hydrogen, lower alkyl or optionally protected hydroxy(lower)alkyl, and R6 is hydrogen or lower alkyl, or pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases in human being and animals.
• Substituted dipeptides having nos inhibiting activity
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06825200B1

  公开（公告）日：2004-11-30

  The present invention a compound represented by the formula (I): where the structural variables R1-R6 are defined herein.

  本发明涉及一种由公式（I）表示的化合物，其中结构变量R1-R6在此定义。
• 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases
  作者：Pierre Koch、Rhalid Akkari、Andreas Brunschweiger、Thomas Borrmann、Miriam Schlenk、Petra Küppers、Meryem Köse、Hamid Radjainia、Jörg Hockemeyer、Anna Drabczyńska、Katarzyna Kieć-Kononowicz、Christa E. Müller

  DOI：10.1016/j.bmc.2013.09.044

  日期：2013.12

  Adenosine receptors and monoamine oxidases are drug targets for neurodegenerative diseases such as Parkinson's and Alzheimer's disease. In the present study we prepared a library of 55 mostly novel tetrahydropyrimido[2,1-f]purinediones with various substituents in the 1- and 3-position (1,3-dimethyl, 1,3-diethyl, 1,3-dipropyl, 1-methyl-3-propargyl) and broad variation in the 9-position. A synthetic strategy to obtain 3-propargyl-substituted tetrahydropyrimido[2,1-f]purinedione derivatives was developed. The new compounds were evaluated for their interaction with all four adenosine receptor subtypes and for their ability to inhibit monoamine oxidases (MAO). Introduction of mono-or di-chloro-substituted phenyl, benzyl or phenethyl residues at N9 of the 1,3-dimethyl series led to the discovery of a novel class of potent MAO-B inhibitors, the most potent compound being 9-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)-dione (21g, IC50 human MAO-B: 0.0629 mu M), which displayed high selectivity versus the other investigated targets. Potent dually active A(1)/A(2A) adenosine receptor antagonists were identified, for example, 9-benzyl-1-methyl-3-propargyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)dione (19f, K-i, human receptors, A(1): 0.249 mu M, A(2A): 0.253 mu M). Several compounds showed triple-target inhibition, the best compound being 9-(2-methoxybenzyl)-1-methyl-3-(prop-2-ynyl)-6,7,8,9-tetrahydro pyrimido [1,2-f]purine-2,4(1H,3H)-dione (19g, K-i A(1): 0.605 mu M, K-i A(2A): 0.417 mu M, IC50 MAO-B: 1.80 mu M). Compounds inhibiting several different targets involved in neurodegeneration may exhibit additive or even synergistic effects in vivo. (C) 2013 Elsevier Ltd. All rights reserved.